Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation with no cure and limited treatment options that often have systemic side effects. In this study, we developed a target-specific system to potentially treat IBD by engineering the probiotic bacterium Escherichia coli...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ACS synthetic biology 2024-08, Vol.13 (8), p.2376-2390
Hauptverfasser:	Weibel, Nathalie, Curcio, Martina, Schreiber, Atilla, Arriaga, Gabriel, Mausy, Marine, Mehdy, Jana, Brüllmann, Lea, Meyer, Andreas, Roth, Len, Flury, Tamara, Pecina, Valerie, Starlinger, Kim, Dernič, Jan, Jungfer, Kenny, Ackle, Fabian, Earp, Jennifer, Hausmann, Martin, Jinek, Martin, Rogler, Gerhard, Antunes Westmann, Cauã
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - genetics Escherichia coli - genetics Escherichia coli - metabolism Humans Inflammation - metabolism Inflammatory Bowel Diseases - therapy Nitric Oxide - metabolism Probiotics Single-Domain Antibodies - genetics Tumor Necrosis Factor-alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!